scholarly journals Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study

2013 ◽  
Author(s):  
Pamela Freda ◽  
Maria Fleseriu ◽  
der Lely Aart Jan van ◽  
Annamaria Colao ◽  
Michael Sheppard ◽  
...  
Keyword(s):  
Phase Iii ◽  
Biochemical Control ◽  
Double Blind ◽  
Octreotide Lar ◽  
Multicenter Phase ◽  
Phase Iii Study

scholarly journals Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Pituitary ◽  
2014 ◽  
Vol 18 (3) ◽  
pp. 385-394 ◽  
Author(s):  
Michael Sheppard ◽  
Marcello D. Bronstein ◽  
Pamela Freda ◽  
Omar Serri ◽  
Laura De Marinis ◽  
...  
Keyword(s):  
Phase Iii ◽  
Extension Phase ◽  
Double Blind ◽  
Multicenter Phase ◽  
Phase Iii Study
Sign in / Sign up

Export Citation Format

Share Document